Company intelligence / Profile preview

Honor Epic

South San Francisco, California, United States

Ownership: Private
Development stage: Other

Overview

Lead program EPI-321 in IND-enabling studies for FSHD with plans for first-in-human trial in early 2024; preclinical data in mice and non-human primates support durable gene activation and silencing.[1]

Therapeutic areas: CardiovascularNeurologyRare Diseases
Modalities: Gene therapy
Industry: Biotech

Partnerships

SOLVE FSHD

Beyond the preview

Go deeper on Honor Epic.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Honor Epic.

Explore the full profile